gsk-2269557
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01462617)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1.Cl- Mol. weight
- 477.01 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314409 ↗
- ChEMBLCHEMBL3545250 ↗
Also known as
- gsk2269557
- gsk2269557
- gsk2269557
- gsk-2269557
- gsk-2269557
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03189589 | Phase 1 | Jun 15, 2017 | GlaxoSmithKline |
| NCT02972905 | Phase 1 | Oct 1, 2016 | GlaxoSmithKline |
| NCT02593539 | Phase 2 | Jul 22, 2016 | GlaxoSmithKline |
| NCT02691325 | Phase 1 | Mar 14, 2016 | GlaxoSmithKline |
| NCT02522299 | Phase 2 | Nov 1, 2015 | GlaxoSmithKline |
| NCT02567708 | Phase 2 | Oct 1, 2015 | GlaxoSmithKline |
| NCT02294734 | Phase 2 | Mar 1, 2015 | GlaxoSmithKline |
| NCT02130635 | Phase 2 | Jul 1, 2014 | GlaxoSmithKline |
| NCT01762878 | Phase 1 | Jan 9, 2013 | GlaxoSmithKline |
| NCT01462617 | Phase 1 | Jul 1, 2011 | GlaxoSmithKline |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 10 | 10 | 2 | 2011 |
1 organizations
Page 1 / 1